利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.012 秒)

    DIAMINES POSSEDANT UNE ACTIVITE MODULATRICE DES CASR
    1.
    发明公开
    DIAMINES POSSEDANT UNE ACTIVITE MODULATRICE DES CASR 审中-公开
    DIAMINE MIT CASR MODULIERENDER AKTIVITAET

    公开(公告)号：EP1409453A1

    公开(公告)日：2004-04-21

    申请号：EP01963065.6

    申请日：2001-08-07

    申请人： CENTRE NATIONAL DELA RECHERCHE SCIENTIFIQUE (CNRS)

    发明人： DAUBAN, Philippe, Marcel ,  DODD, Robert, Hugh ,  FAURE, Hélène, Véronique ,  RUAT, Martial ,  POTIER, Pierre, Jean-Paul ,  KESSLER, Albane

    IPC分类号： C07C311/29 ,  C07C211/36 ,  C07C311/20 ,  A61K31/18 ,  A61K31/137 ,  C07D203/26

    CPC分类号： C07C311/29 ,  C07B2200/07 ,  C07C211/36 ,  C07C311/20 ,  C07C2601/14 ,  C07D203/26

    摘要： The invention concerns diamines of general formula (I), wherein: A represents a group A1 or A2 of general formula (II); B represents a group B1 or B2 of general formula (III); X represents a SO2, CH2, C=O or COO; Y------Z represents a group of formula CH(R25)-CH(R26) or CH(R27)=CH(R28),and R1 to R28, identical or different, represent independently of one another, a hydrogen or halogen atom or an alkyl, cycloalkyl, CN, NO2, hydroxy, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, arylalkylamino, diarylamino diarylalkylamino, trihalogenoalkyl or trihalogenoalkoxy group, provided that in the group A1, at least one of the radicals R1, R2, R3, R4 or R5 represents the hydrogen atom when the other four do not represent the hydrogen atom and in the group B1, at least one of the radicals R13, R14, R15, R16 or R17 represents the hydrogen atom when the other four do not represent the hydrogen atom, and their salts with a pharmaceutically acceptable acid, in the form of racemic mixture or their optically pure isomers. The invention also concerns their preparation, pharmaceutical compositions comprising them and their use as CaSR activity modulator and as medicine particularly designed for the treatment of psychological diseases and disorders involving CaSR activity modulation.

    摘要翻译： 本发明涉及通式（I）的二胺，其中：A表示通式（II）的基团A1或A2; B表示通式（III）的基团B1或B2; X表示SO 2，CH 2，C-O或COO; y Z表示式CH（R 25）-CH（R 26）或CH（R 27） - （R 28）的基团，R 1〜R 28相同或不同，彼此独立地表示氢或 卤素原子或烷基，环烷基，CN，NO 2，羟基，芳基，芳烷基，烷氧基，芳氧基，氨基，烷基氨基，二烷基氨基，环烷基氨基，芳基氨基，芳基烷基氨基，二芳基氨基二芳基烷基氨基，三卤代烷基或三卤代烷氧基， 条件是在组A1中，当其它四个不表示氢原子时，基团R 1，R 2，R 3，R 4或R 5中的至少一个表示氢原子，在基团B1中，基团R 13， R 14，R 15，R 16或R 17表示当外消旋混合物或其光学剂形式的其它四个不表示氢原子时，氢原子及其与药学上可接受的酸的盐 lly孔异构体。 本发明还涉及它们的制备，包含它们的药物组合物及其作为CaSR活性调节剂的用途，以及用于治疗涉及CaSR活性调节的心理疾病和病症的药物。

    COMPOSES POSSEDANT UNE ACTIVITE CALCIMIMETIQUE
    2.
    发明公开
    COMPOSES POSSEDANT UNE ACTIVITE CALCIMIMETIQUE 有权
    CONNECTIONS CALCIMIMETISCHER影响

    公开(公告)号：EP1284963A1

    公开(公告)日：2003-02-26

    申请号：EP01938319.9

    申请日：2001-05-23

    申请人： CENTRE NATIONAL DELA RECHERCHE SCIENTIFIQUE (CNRS)

    发明人： RUAT, Martial ,  DODD, Robert ,  FAURE, Hélène, Véronique ,  DAUBAN, Philippe, Marcel ,  KESSLER, Albane ,  POTIER, Pierre, Jean-Paul

    IPC分类号： C07D209/14 ,  A61K31/4045 ,  A61P5/18 ,  C07D209/42

    CPC分类号： C07D209/42 ,  C07D209/14

    摘要： The invention concerns compounds of general formula (I) wherein: the group X represents a -NR4, -CH = N or -CHR5-NR4- group; the group Y represents an oxygen or sulphur atom or a NR, -CR5, -CHR5-, -CR5=CR6- or -CHR5-CHR6 group provided that when group X represents the -CH=N- or -CHR5-NR4- group, group Y represents an oxygen or a sulphur atom or a Nr, -CR5 or -CHR group; the group R represents a hydrogen atom or an alkyl, aryl or aralkyl group; the groups R1, R5 and R6, identical or different, represent each a hydrogen or halogen atom or an alkyl or alkoxy group; the group R2 represents a hydrogen atom or an alkyl group; the group R3 represents an aryl group; and the group R4 represents a hydrogen atom, an alkyl, aryl, aralkyl, alkylsulphonamide, arylsulphonamide or aralkylsulphonamide group; and their salt with a pharmaceutically acceptable acid, in the form of a racemic mixture and their optically pure isomer. The invention also concerns their preparation, pharmaceutical compositions containing them and their use as CaSR activity modulator and as medicine for preferably treating diseases or physiological disorders involving the intervention of CaSR activity modulation.